Roche Holding AG's arthritis and lymphoma medicine Rituxan cut the need for insulin treatment among patients with type 1 diabetes after a year, a study found.
"It is unlikely that treatment with rituximab as administered in this study would be optimal," researchers led by Mark Pescovitz at the Indiana University School of Medicine in Indianapolis said in the study. Developed by Genentech Inc., which Roche fully acquired earlier this year, Rituxan is approved for use in both non-Hodgkin's lymphoma and rheumatoid arthritis. The drug in February won European regulatory backing as a leukemia treatment. Rituxan generated 1.51 billion Swiss francs ($1.5 billion) in sales during the third quarter. While there were more adverse events among patients given their first dose of Rituxan compared with those given a placebo, the reactions appeared to be "minimal," the study found.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RESEARCH & TECHNOLOGY|
|Article Type:||Brief article|
|Date:||Nov 30, 2009|
|Previous Article:||Women younger than 65 years old and men younger than 55 with acute chest pain benefit most from cardiac CT angiography (CTA) for suspected acute...|
|Next Article:||The number of Americans with diabetes may almost double in 25 years, and the annual cost of treating them may triple to $336 billion, according to a...|